SUMMARY INTRODUCTION: Sarcopenia is characterized by the involuntary loss of lean body mass associated with a progressive reduction of muscle strength. OBJECTIVE: To determine the prevalence of sarcopenia in kidney transplant recipients and its association with the determining factors that control muscle homeostasis. METHODS: We evaluated renal transplant recipients undergoing follow-up at the University Hospital of the Federal University of Maranhão from June 2017 to July 2018 and who met the inclusion criteria. Sarcopenia was defined according to the European criteria. The skeletal muscle mass index was measured by dual-energy radiological absorptiometry; the values <7,26 kg/m2 for men and <5,5 kg/m2 for women were adopted for muscle depletion. For handgrip strength, values of <30 kg for men and <20 kg for women were considered as reduced muscle strength. In both sexes, the cutoff point for walking speed was <0,8 m/s. RESULTS: We evaluated 83 renal transplant recipients with a mean age of 48.8 ± 12,1 years and predominantly males (57,8%). The prevalence of sarcopenia was 19,3%. Among individuals without sarcopenia, 17,9% had a decrease in handgrip strength and 40,3% has altered gait speed. DISCUSSION: Individuals submitted to renal transplant may develop sarcopenia while still young and already present altered muscle function and strength even before the depletion of lean body mass. CONCLUSION: Early diagnosis may allow the prevention of sarcopenia and provide a better quality of life for patients.
Background: Disorders of mineral metabolism occur in most patients with chronic kidney disease (CKD). The aim of this work was to correlate serum parathyroid hormone (PTH) levels with urinary magnesium excretion in patients with non-dialysis CKD. Methods: Cross-sectional study with patients with CKD undergoing non-dialysis treatment in stages 3A, 3B and 4. Concentrations of creatinine, magnesium, calcium, phosphorus, parathyroid hormone, vitamin D and alkaline phosphatase were determined in blood samples. The assessment of urinary magnesium levels was performed by means of total daily excretion and by the excretion fraction (FEMg). Results: The study evaluated 163 patients with mean age of 60.7 ± 11.7 and 51.0% were male. A positive correlation was observed between PTH and alkaline phosphatase (r = 0.26; p = 0.006) and FEMg (r = 0.17; p = 0.020). Calcium (r = -0.23; p = 0.002), magnesium in 24-hour urine (r = -0.18; p = 0.020) and estimated glomerular filtration rate (r = -0.47; p = 0.001) demonstrated negative correlation with PTH. Conclusion: Elevated levels of PTH correlated positively with FEMg, regardless of the presence of serum magnesium alterations, and FEMg can be used as another indicator for the treatment of hyperparathyroidism.
Direitos para esta edição cedidos à Atena Editora pelos autores. Todo o conteúdo deste livro está licenciado sob uma Licença de Atribuição Creative Commons. Atribuição-Não-Comercial-NãoDerivativos 4.0 Internacional (CC BY-NC-ND 4.0). O conteúdo dos artigos e seus dados em sua forma, correção e confiabilidade são de responsabilidade exclusiva dos autores, inclusive não representam necessariamente a posição oficial da Atena Editora. Permitido o download da obra e o compartilhamento desde que sejam atribuídos créditos aos autores, mas sem a possibilidade de alterá-la de nenhuma forma ou utilizá-la para fins comerciais. A Atena Editora não se responsabiliza por eventuais mudanças ocorridas nos endereços convencionais ou eletrônicos citados nesta obra. Todos os manuscritos foram previamente submetidos à avaliação cega pelos pares, membros do Conselho Editorial desta Editora, tendo sido aprovados para a publicação.
1 Fatores de risco para hiperglicemia em pacientes transplantados renais Risk factors for hyperglycemia in kidney transplant patients Factores de riesgo de hiperglucemia en pacientes con trasplante renalResumo O objetivo desse estudo foi analisar os fatores de risco associados com a hiperglicemia em pacientes transplantados renais. Para tanto, foi realizado um estudo transversal retrospectivo Research, Society and Development, v. 9, n.2, e145922143, 2020 (CC BY 4.0) | ISSN 2525-3409 | DOI: http://dx.doi.org/10.33448/rsd-v9i2.2143 2 com coleta de dados clínicos, laboratoriais e antropométricos de pacientes que realizaram transplante renal. Para identificar fatores associados à hiperglicemia, foi realizada análise bivariada e multivariada com modelos hierarquizados. Dentre os 89 pacientes avaliados, o índice de massa corporal revelou 47,1% dos pacientes eutróficos e 34,7% com excesso de peso. Observou-se que 28% dos pacientes apresentavam hiperglicemia e 82%, 86,5%, 87,6% e 91% tinham creatinina, ureia, hemoglobina, e hematócrito alterados, respectivamente. Foi encontrada associação estatística significativa (p<0,05) de hiperglicemia com obesidade II e III, e pacientes com obesidade II e III tinham mais chances de ter glicemia e potássio alterados, (RP=4,91; IC: 1,04, p<0,001; RP=2,23; IC: 1,09-4,54, p=0,026), respectivamente.Verificou-se que a obesidade e a hipercalemia foram fatores de risco para a hiperglicemia em pacientes transplantados renais. Palavras-chave: Transplante de rim; Estado nutricional; Glicemia; Avaliação nutricional;Complicações metabólicas. AbstractThe aim of this study was to analyze the risk factors associated with hyperglycemia in renal transplant patients. For this, a retrospective cross-sectional study was conducted to collect clinical, laboratory and anthropometric data from patients who underwent kidney transplantation. To identify factors associated with hyperglycemia, a bivariate and multivariate analysis was performed with hierarchical models. Among the 89 patients evaluated, the body mass index revealed 47.1% of eutrophic patients and 34.7% overweight.28% of the patients had hyperglycemia and 82%, 86.5%, 87.6% and 91% had altered creatinine, urea, hemoglobin, and hematocrit, respectively. A statistically significant association (p <0.05) of hyperglycemia with obesity II and III was found, and patients with obesity II and III were more likely to have altered glycemia and potassium, (PR = 4.91; CI:1.04, p <0.001; RP = 2.23; CI: 1.09-4.54, p = 0.026), respectively. Obesity and hyperkalemia were found to be risk factors for hyperglycemia in renal transplant patients. ResumenEl objetivo de este estúdio fue analizar los factores de riesgo asociados con la hiperglucemia en pacientes con trasplante renal. Com este fin, se realizó un estudio transversal retrospectivo para recopilar datos clínicos, de laboratorio y antropométricos de pacientes sometidos a
Background: Disorders of mineral metabolism occur in most patients with chronic kidney disease (CKD). The aim of this work was to correlate serum parathyroid hormone (PTH) levels with urinary magnesium excretion in patients with non-dialysis CKD.Methods: Cross-sectional study with patients with CKD undergoing non-dialysis treatment in stages 3A, 3B and 4. Concentrations of creatinine, magnesium, calcium, phosphorus, parathyroid hormone (PTH), 25-hydroxyvitamin D [25(OH)D] and alkaline phosphatase (ALP) were determined in blood samples. The assessment of urinary magnesium levels was performed by means of total daily excretion and by the excretion fraction (FEMg). Results: The study evaluated 163 patients with a mean age of 60.7 ± 11.7 years and 51.0% were male. In the highest quartile of PTH (> 89.5pg / ml), the mean levels of FEMg and ALP were higher (p <0.05), as well as the levels of serum calcium and eGFR were lower (p <0.05). In the unadjusted regression analysis, the following variables were related to serum PTH levels: FEMg (odds ratio (OR) = 1.12; 95% confidence intervals (CI): 1.02–1.23), Calcium (OR = 0.45; 95% CI: 0.22-0.90), ALP (OR = 1.02; 95% CI: 1.00-1.03) and eTFG (OR = 0.92; 95% CI: 1.00-1.03). After an adjusted analysis, only one FEMg and ALP will remain correlated with PTH. Conclusion: In patients with non-dialysis CKD, with higher levels of PTH, higher mean columns of ALP and FEMg, and lower levels of serum calcium and eGFR. FEMg and ALP were some variables that remained associated with PTH.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.